All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study -

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Information type: Randomised controlled trials
Source: Lancet Public Health
Specialities: Infection and infectious diseases
Summary
The HALLMARK-DUAL study (n=307) demonstrated that daclatasvir plus asunaprevir provided high SVR12 response rates in treatment-naïve (90%), non-responder (82%), and ineligible, intolerant, or ineligible and intolerant patients (82%) with HCV genotype 1b infection.
UKMi comment
A related editorial discusses the implications of these findings in the context of interferon- and ribavirin-free regimens for treatment of hepatitis C.
Related links: Editorial